CPDR is a comprehensive research program to study prostate cancer and prostate disease in the triservice military health care system. Established in 1992 (Public Law 102-172), CPDR has received funding from Congress through the U.S. Army Medical Research and Materiel Command since 1992. Since its inception, the program has progressed in an outstanding manner as evidenced by:
Multi-center National Database Program
The largest, most comprehensive prostate cancer database in the United States. Involving the Army, Air Force, and Navy at multiple military medical centers, the program is a model for interservice cooperation and research collaboration. With approximately 26,000 prostate cancer survivors enrolled to date, the CPDR database is rapidly becoming a national resource.
Basic Science Research Program
The only free-standing prostate cancer research center in the U.S. This 20,000 square foot state-of-the-art basic science laboratory facility is attracting the best and brightest to study the disease. Using blood and tissues collected from volunteering military beneficiaries, the CPDR laboratory has amassed a large bank of prostate cancer specimens that are serving to unravel the genetics of the disease.
Clinical Research Program
A prostate cancer clinical trials center at Walter Reed National Military Medical Center (WRNMMC). Recognizing that too few men have participated in clinical trials in the past, this Center will make state-of-the-art research trials available to deserving military health beneficiaries. The Center is open to all beneficiaries worldwide.
The information provided on this web site is for informational purposes only and is not intended to replace medical advice. You should review the information carefully with your physician(s) before adopting any of this information into your current medical plan. CPDR provides clinical and research information that is complete and in accord with the standards in existence at the time of publication. However, CPDR does not warrant that the information contained herein is in every respect accurate or complete and CPDR is not responsible for any errors or omissions or for the results obtained from the use of this information. CPDR makes no representations or warranties with resect to any treatment, action, process or application of medication by any person following the information provided by CPDR. CPDR will not be liable for any damages arising from the use of this information.
The opinions and assertions contained herein are the private views of the author and are not to be construed as reflecting the views of the US Department or Defense.
Please consult with your doctor before adopting any of the information found on this site into your current healthcare plan.
August 21, 2014
ERG Monoclonal Antibody [9FY] Patent Issued To The Uniformed Services University Of The Health Sciences Center For Prostate Disease Research & Biocare Medical
Concord, CA – The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has been awarded a patent in the United States (Patent No: US 8,765,916 B2) and Europe for ERG monoclonal antibodies. The patent is pending in Australia, Canada and Japan. ERG mouse antibody 9FY is a rigorously characterized antibody for its specificity of the ERG protein detection among the closely related members of the ETS transcription factor family in biological specimens.
Read Full Article
August 6, 2014
Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints
Redwood City, CA – PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a ...
Read Full Article
WRNMMC UsToo! Newsletter
Read the AUGUST 2014 Newsletter